The heart of the matter: Cardiometabolic care in youth with psychosis

Early Intervention in Psychiatry

Volumn 6, Issue 3, 2012, Pages 347-353

  Curtis, Jackie ^a,b   Newall, Hannah D ^b   Samaras, Katherine ^b,c,d  

^a Bondi Centre   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Intervention; Metabolic syndrome; Psychosis; Youth

Indexed keywords

ARIPIPRAZOLE; METFORMIN; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; BODY WEIGHT; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET; EARLY DIAGNOSIS; ETHNICITY; EXERCISE; FAMILY HISTORY; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC DISORDER; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; RISK FACTORS; WEIGHT GAIN; YOUNG ADULT;

EID: 84864296104     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2011.00315.x     Document Type: Article

References (32)

1. McGorry P, Killackey E, Lambert T etal. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39: 1-30.
2. McGorry PD, Killackey E, Yung AR. Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust 2007; 187: S8-S10.
3. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-73.
4. De Hert M, Schreurs V, Sweers K etal. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008; 101: 295-303.
5. Australian Bureau of Statistics. National Health Survey: Summary of Results Australia. 2009 [Cited 25 Aug 2009.] Available from URL:
6. Alberti K, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-62.
7. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. Diabetes Care 2008; 31: 587-9.
8. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-8.
9. Lambert TJ, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009; 190: 16.
10. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-21.
11. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007; 68: 4-7.
12. Lambert TJ, Chapman LH, Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-8.
13. Waterreus AJ, Laugharne JD. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 2009; 190: 185-9.
14. Verma S, Liew A, Subramaniam M, Poon LY. Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis. Aust N Z J Psychiatry 2009; 43: 812-7.
15. Patel JK, Buckley PF, Woolson S etal. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009; 111: 9-16.
16. Perez-Iglesias R, Mata I, Pelayo-Teran JM etal. Glucose and lipid disturbances after 1year of antipsychotic treatment in a drug-naive population. Schizophr Res 2009; 107: 115-21.
17. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of anti psychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008; 193: 101-7.
18. Wu RR, Zhao JP, Guo XF etal. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008; 165: 352-8.
19. Wu RR, Zhao JP, Jin H etal. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299: 185-93.
20. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL etal. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006; 67: 1253-60.
21. Beebe LH, Tian L, Morris N, Goodwin A, Allen SS, Kuldau J. Effects of exercise on mental and physical health parameters of persons with schizophrenia. Issues Ment Health Nurs 2005; 26: 661-76.
22. Marzaloni S, Jensen B, Melville P. Feasibility and effects of a groupbased resistance and aerobic exercise program for individuals with schizophrenia: a multidisciplinary approach. Ment Health Phys Act 2009; 2: 29-36.
23. Bjorkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol 2011; 25: 299-305.
24. Bushe CJ, Bradley AJ, Doshi S, Karagianis J. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. Int J Clin Pract 2009; 63: 1743-61.
25. Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol 2011; doi: 10.1097/YIC.0b013e32834d0a5b [Epub ahead of print].
26. NSW Department of Health. Physical Health Care of Mental Health Consumers: Guidelines. May 2009. [Cited 25 Aug 2009.] Available from URL:
27. Curtis J, Henry C, Watkins A, Newall H, Samaras K, Ward PB. Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study. Early Interv Psychiatry 2011; 5: 108-14.
28. Ibáñez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F. Early metformin therapy (age 8-12years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab 2011; 96: E1262-7.
29. Lavine JE, Schwimmer JB, Van Natta ML etal. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-68.
30. Shiers D, Jones PB, Field S. Early intervention in psychosis: keeping the body in mind. Br J Gen Pract 2009; 59: 395-6.
31. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother 2008; 61: 238-45.
32. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 1350; 327: 1350-5.